A share price of Ocular Therapeutix Inc [OCUL] is currently trading at $5.02, up 5.91%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The OCUL shares have gain 8.07% over the last week, with a monthly amount drifted -40.80%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ocular Therapeutix Inc [NASDAQ: OCUL] stock has seen the most recent analyst activity on February 09, 2024, when BofA Securities initiated its Buy rating and assigned the stock a price target of $15. Previously, Robert W. Baird started tracking the stock with Outperform rating on April 21, 2023, and set its price target to $18. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $17 on August 10, 2021. H.C. Wainwright downgraded its rating to a Neutral. Berenberg started tracking with a Buy rating for this stock on December 17, 2020, and assigned it a price target of $27. In a note dated November 13, 2020, Raymond James reiterated an Strong Buy rating on this stock and boosted its target price from $15 to $25.
Ocular Therapeutix Inc experienced fluctuations in its stock price throughout the past year between $2.00 and $11.31. Currently, Wall Street analysts expect the stock to reach $17 within the next 12 months. Ocular Therapeutix Inc [NASDAQ: OCUL] shares were valued at $5.02 at the most recent close of the market. An investor can expect a potential return of 238.65% based on the average OCUL price forecast.
Analyzing the OCUL fundamentals
Trailing Twelve Months sales for Ocular Therapeutix Inc [NASDAQ:OCUL] were 58.44M which represents 5.16% growth. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -1.41%, Pretax Profit Margin comes in at -1.38%, and Net Profit Margin reading is -1.49%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -3.11 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.84.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.76 points at the first support level, and at 4.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.35, and for the 2nd resistance point, it is at 5.69.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ocular Therapeutix Inc [NASDAQ:OCUL] is 6.66. Also, the Quick Ratio is 6.59, while the Cash Ratio stands at 5.62. Considering the valuation of this stock, the price to sales ratio is 12.77, the price to book ratio is 6.33.
Transactions by insiders
Recent insider trading involved SUMMER ROAD LLC, 10% Owner, that happened on Feb 26 ’24 when 0.93 million shares were purchased. President and CEO, Mattessich Antony C. completed a deal on Jan 31 ’24 to sell 18338.0 shares. Meanwhile, Chief Medical Officer Ozden Rabia Gurses sold 7764.0 shares on Jan 31 ’24.
